title: [Efficacy and safety of ustekinumab in psoriatic arthritis after anti-TNFα failure in routine practice].
abstract: OBJECTIVE
  Evaluation of effectiveness and safety of ustekinumab in psoriatic arthritis after anti-TNFα failure.
  
  
  METHODS
  We conducted a retrospective and monocentric study. The evaluation of articular and cutaneous effectiveness by the patient was made with numeric scale and satisfaction scale and by the physician during a rhumatological-dermatological consultation. The safety was analyzed by collecting the adverse effects.
  
  
  RESULTS
  Nine patients with anti-TNF failure were included. Five of them stopped the treatment because of severe adverse effects. The mean duration treatment of ustekinumab was 24 months. Articular and cutaneous effectiveness were respectively 4.4/10 and 6.7/10. Two thirds of the patients were "satisfied" and one third could stop any analgesic treatment. The mean PASI score decreased from 8.4 to 1.7 after 3 months treatment. Only minor adverse effects were collected and there were no recidivism of the adverse effects observed with anti-TNFα.
  
  
  CONCLUSIONS
  Ustekinumab is an effective and safe alternative for patients with anti-TNFα failure in psoriatic arthritis.
authors.affiliation: Service de rhumatologie, hôpital Maison-Blanche, CHU de Reims, 45, rue Cognac-Jay, 51092 Reims, France. Electronic address: docteur.m.michel@gmail.com.
authors.forename: Matthias
authors.initials: M
authors.lastname: Michel
authors.affiliation: Service de dermatologie, hôpital Robert-Debré, CHU de Reims, 51092 Reims, France.
authors.forename: Ziad
authors.initials: Z
authors.lastname: Reguiai
authors.affiliation: Service de rhumatologie, hôpital Maison-Blanche, CHU de Reims, 45, rue Cognac-Jay, 51092 Reims, France.
authors.forename: Marion
authors.initials: M
authors.lastname: Fauconier
authors.affiliation: Service de rhumatologie, hôpital Maison-Blanche, CHU de Reims, 45, rue Cognac-Jay, 51092 Reims, France.
authors.forename: Pascal
authors.initials: P
authors.lastname: Brochot
authors.affiliation: Service de rhumatologie, hôpital Maison-Blanche, CHU de Reims, 45, rue Cognac-Jay, 51092 Reims, France.
authors.forename: Jean-Paul
authors.initials: JP
authors.lastname: Eschard
authors.affiliation: Service de rhumatologie, hôpital Maison-Blanche, CHU de Reims, 45, rue Cognac-Jay, 51092 Reims, France; EA 3797, université de Reims Champagne Ardenne, faculté de médecine, 51095 Reims, France.
authors.forename: Jean-Hugues
authors.initials: JH
authors.lastname: Salmon
mesh_terms: D000328:Adult; D000368:Aged; D015535:Arthritis, Psoriatic / Q000188:drug therapy* / Q000523:psychology; D003879:Dermatologic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006229:Hand Dermatoses / Q000139:chemically induced; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D017060:Patient Satisfaction; D012189:Retrospective Studies; D017211:Treatment Failure; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D000069549:Ustekinumab / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D003879:Dermatologic Agents; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D000069549:Ustekinumab
keywords: Anti-TNFα; Psoriatic arthritis; Rhumatisme psoriasique; Ustekinumab